Journal of Integral Sciences
[An International Open Access Journal]
Available at www.jisciences.com ISSN: 2581-5679

EMERGING PERSPECTIVES ON LATENT AUTOIMMUNE DIABETES IN ADULTS: A DISTINCT DIABETES MELLITUS VARIANT

P. MYTHILI[1], K. LIKHITHA VAISHNAVI[1], P. HEMA[1], CH. SAITEJA[1], PRAVEEN KUMAR UPPALA[2], MADDI RAMAIAH[3]

[1]B.Pharmacy, Maharajah's College of Pharmacy, Vizianagaram, Andhra Pradesh, India
[2]Assistant Professor, Department Pharmacology, Maharajah's College of Pharmacy, Vizianagaram, Andhra Pradesh, India.
[3]Professor and Principal, Maharajah's College of pharmacy, Vizianagaram, Andhra Pradesh, India

Received: 12-02-2026 Revised: 19-03-2026 Accepted: 27-04-2026

ABSTRACT

Latent Autoimmune Diabetes in Adults (LADA) is an autoimmune disease in which the immune system slowly attacks and destroys insulin-producing beta cells in the pancreas. It is different from Type 1 diabetes, which is generally due to the autoimmune destruction of insulin-producing cells, pancreatic beta cells, LADA variant in diabetes progresses more gradually and often intensify later in life. This slower onset mimics Type 2 diabetes mellitus, differentiating it from other diabetes mellitus forms. LADA comprises features of both Type 1 and Type 2 diabetes, which apparently leads to misdiagnosis as Type 2 in its early phases. As the disease progresses, pancreatic insulin production declines consistently, emphasize the value of accurate diagnosis and personalized management to prevent various serious complications. Research shows that about 10% of individuals initially diagnosed with Type 2 diabetes actually have LADA, it is traceable by circulating islet autoantibodies. These patients poorly respond to oral medications like sulfonylureas- Glimepiride, Glipizide. LADA identification is pivotal for improving effective treatment, though it remains challenging due to limited directions for antibody screening in adult-onset cases. Greater knowledgeon LADA enhances its clinical handling and increases awareness on the broader spectrum of autoimmune diabetes and about it's different variants like- Type 1 diabetes, Type 2 diabetes mellitus, Gestational diabetes, Type 5 diabetes, MODY- Maturity onset diabetes in young.

Keywords: *Latent auto-immune diabetes in adults (LADA), Pancreatic beta cells, Diabetes mellitus, Emphasize, Sulfonylureas.*

***Corresponding Author**
Praveen Kumar Uppala

DOI: https://doi.org/10.37022/jis.v9i1.138

Produced and Published by
South Asian Academic Publications

INTRODUCTION

Diabetes Mellitus (DM) is a chronic metabolic condition marked bygradually increasing blood sugar levels, rooting from problems with insulin production or its effectiveness. Eventually, Diabetes mellitus can trigger severe issues like neruopathy, diabetic retinopathy, cardiovascular disease (heart attack, stroke), foot ulcers, frequent infections, kidney failure, skin conditions, and sexual health challenges in both men and women. A critical short-lived risk is diabetic ketoacidosis-it's a condition develops when the body can't make enough insulin,it is a life- threatening and dangerous condition triggered by extreme insulin shortages leads to breakdown of fat too quickly resulting in increased blood acidity [1].

Diabetes includes a spectrum, from Type 1- caused by an autoimmune attack destroying pancreatic beta cells and resulting in minute to no insulin production. Type 2, which mainly stems from the body's resistance to insulin. Latent Autoimmune Diabetes in Adults (LADA), often called "Type 1.5 diabetes," bridges these two with features of both and advances more slowly than classic Type 1. The American Diabetes Association classifies LADA as a slower-onset form of Type 1 diabetes, whereas the World Health Organization labels it immune-triggered diabetes that develops gradually.

`

Fig 1: Classification of Diabetes Mellitus

LADA is an autoimmune diabetes form that attacks adults of age more than 30. The Immunology of Diabetes Society outlines the core diagnostic standards:

- Begins after age 30.
- Autoantibodies triggering pancreatic beta cells.
- Insulin is not needed for at least six months from post-diagnosis.

LADA shares autoimmune origins with Type 1 diabetes, involving beta-cell autoantibodies-most notably those targeting glutamic acid decarboxylase- even though the beta-cell damage unfolds more gradually. As a result, it typically presents with mild to moderate hyperglycemia at first, which is frequently misdiagnosed as Type 2 diabetes [2]

LADA differs widely:

- Some patients show strong antibody responses, maintain a low BMI, and quickly become reliant on insulin.
- Others exhibit minimal antibodies, marked insulin resistance, and a more gradual slide toward dependence.

Due to this divergent, most patients primarily manages with oral medications but eventually need insulin as blood glucose control slips.

LADA majorly mimics like Type 2 diabetes because it observed up in adults and progresses slowly at first,but since it's autoimmune disease, it can't be fixed with diet and exercise like typical Type-2 diabetes. Beta cells of particular LADA effected patient fails much faster than in standard Type 2 diabetes cases.

Physicians often misdiagnose it as type 2 diabetes, especially in lean, active individuals who receive that early classification- making it wise to confirm LADA through objectified tests.

LADA mimics Type 2 in its adult onset, but as an autoimmune disease, it withstanding change through diet or exercise alone. Beta-cell failure progresses in LADA compared to Type 2. It's frequently misdiagnosed as Type 2, especially if you're at a healthy weight, active individual with Type 2- prompting consideration of LADA testing [3].

Table 01: Comparative Analysis of Different Types of Diabetes Mellitus

Types of Diabetes	Genetic Factors affecting the type	Main Cause	Symptoms	Diagnosis	Treatment
TYPE-1 DIABETES MELLITUS	Strong association with **HLA-DR3, HLA-DR4 genes**	Autoimmune attack on pancreatic beta cells	Frequent urination, excessive thirst, weight loss, fatigue	Fasting glucose, HbA1c, auto-antibodies (GAD, IA-2), low C-peptide	Lifelong **insulin therapy**, glucose monitoring
TYPE-1.5 LADA- LATENT AUTOIMMUNE DIABETES IN ADULTS	Similar autoimmune genes as Type-1 (HLA variants)	Autoimmune process similar to Type 1 but slower	Similar to Type-1 but slower onset	Same antibody tests (GAD antibodies common)	Initially oral drugs but eventually insulin
TYPE-2 DIABETES MELLITUS	Polygenic; variants in **TCF7L2, FTO, PPARG** etc.	Insulin resistance + beta-cell dysfunction	Increased thirst, urination, fatigue, blurred vision, obesity common	Fasting glucose, HbA1c, oral glucose tolerance test	Lifestyle modification, oral drugs (metformin), sometimes insulin
GESTATIONAL DIABETES	Genetic predisposition + pregnancy hormones	Hormonal changes of pregnancy causing insulin resistance	Often mild or no symptoms; may include thirst and fatigue	Oral glucose tolerance test during pregnancy	Diet control, glucose monitoring, sometimes insulin

MODY- MATURITY-ONSET DIABETES IN YOUNG	Mutations in **HNF1A, HNF4A, GCK, PDX1** etc.	Mutation in genes regulating insulin production	Mild hyperglycemia, sometimes asymptomatic	Genetic testing + family history + glucose tests	Depends on subtype (often sulfonylurea's or diet control)
TYPE-5 DIABETES MELLITUS	Not strongly genetic; linked more to nutritional/environmental factors	Long-term protein-energy malnutrition damaging pancreas	Weight loss, weakness, symptoms of malnutrition + hyperglycemia	Blood glucose levels + nutritional history	Nutritional rehabilitation + insulin or oral agents

SYMPTOMS OF LADA

- Excessive thirst (polydipsia)
- Frequent urination, particularly at night (polyuria)
- Unintended weight loss
- Vision that's out of focus
- Numbness or tingling, along with fatigue

Outlook for Type 1.5 Diabetes (LADA)

Patients with type 1.5 diabetes can expect a lifespan comparable to those with other diabetes types provided they keep blood glucose levels stable. Long-term increased blood sugar trigger complications like kidney disease, diabetic retinopathy ,cardiovascular problem and neuropathy all these effects can worsen the outcomes

While type 1 diabetes significantly shortens lifespan in the past, new treatments have changed the outcomes, allowing large people to lead long, vibrant lives today. In LADA, beginning insulin therapy promptly safeguards the pancreas's beta cells, making quick and precise diagnosis crucial [4].

LADA patients also deals with a higher risk of remaining autoimmune conditions, like thyroid issues, in comparison to people those with type 2 diabetes. Poor diabetes control can slow wound healing and leads to major infection risks too.

Prevention and Clinical Management of LADA

There are no specific strategies to prevent Latent Autoimmune Diabetes in Adults (LADA), or Type 1.5 diabetes, underlying cause is autoimmune and genetic triggers, similar to Type 1 diabetes. The solution to reduce LADA prominence lies in prompt, accurate diagnosis and intercede to delay complications.

LADA represents an autoimmune diabetes variant that mostly occurs in adulthood. Apart from classic Type 1, individuals with LADA often can lead months or longer without needing insulin post-diagnosis. It overlie with both Type 1 diabetes and Type 2diabetes in genetic, immune, and metabolic features, but its consistent progression apparently leads to prior misclassification as Type 2diabetes mellitus.

Although LADA's precise causes stays unclear, habituating healthier habits- like balanced diet, regular exercise- workouts, and maintaining proper weight-can help in reducing its advancement, analogousto Type 2 diabetes [5].

Optimum care for LADA needs a team-based, holistic strategy which involves primary care physicians, endocrinologists, diabetes specialists, and dietitians. enduring its underlying mechanisms, symptoms, and diagnostic markers which is crucial for differentiating it from other diabeticvariants and evading errors.

Treatment typically involves lifestyle adjustments, medications, and accurate intake of insulin. Early detection and Intervention pathways improves results by upgrading better control and minimum issues.

A team-based approach in healthcare professions is necessary for effectively managing LADA, as it improves patient education, enhances glycemic control, and diminishes the likelihood of complications.

Objectives

- Differentiate LADA apart from type 2 diabetes mellitus using autoantibody tests in the diagnostic procedures, allowance with personalized treatment plans.
- Assess LADA patients through glucose monitoring, autoantibody screening, and complication checks to refine therapy and boost outcomes.
- Examine diagnostic and treatment approaches for LADA to support smarter clinical choices and better results.
- Promote clear teamwork among doctors, endocrinologists, and educators to elevate LADA patient care.

ETIOLOGY OF LADA

The progression of Latent Autoimmune Diabetes in Adults (LADA) roots primarily from genetic and immune-related mechanisms. As like the type 1 diabetes, specific human leukocyte antigen (HLA) gene variants raise the risk by influencing immune function, it drives the autoimmune destruction of pancreatic beta cells [6]. The accurate triggering for this beta-cell attack still remained unclear.

Fig 02: LADA Mechanism

Environmental and sedentary lifestyle influences, eminent in type 2 diabetes, and well-explored in LADA owing to research limitations like the need for widespread autoantibody screening in adult-onset cases, limited control groups, rare tentative diagnosis, lifestyle data, and study cohorts.

In LADA, like in type 1 diabetes, the immune system steeply eliminates insulin-producing beta cells, gradually necessitating insulin treatment- unlike contrast from type 2 diabetes, where insulin resistance exponentiate from a mix of genetics, poor diet, inactivityand over-weight.

LADA is a mixed variant of both the features of type 1 and type 2 diabetes: it involves autoimmune beta-cell dissipation like type 1, but may also include type 2 diabetes elements like- such as family history of autoimmunity, obesity-driven insulin resistance, huge body mass index, increased waist-to-hip ratios, low birth weight, massive sugar-sweetened beverage consumption and smoking. Protective factors include-regular exercise, moderate alcohol use, and diets lavish in fatty fish [7].

Significantly, some research connects that high coffee consumption (over two cups daily) can elevate LADA risk, though more confirmation is necessary. Although not only tied to the environment, these elements can still effects autoimmune responses in those who are susceptible individuals to them.

EPIDEMIOLOGY OF LADA

Latent Autoimmune Diabetes in Adults (LADA) considered as one of the leading autoimmune types of diabetes among grown-ups, but its occurrence changes noticeably depending on where individuals live and their indigenous backgrounds.

Research expose that a significant part of individuals first labelled with type 2 diabetes apparently carry signs of autoimmunity. A extensive European study through multiple centers. for example, found islet autoantibodies in roughly 9-10% of adults newly diagnosed with diabetes. In the UK, about 15% of those thought to have type 2 diabetes showed positive autoantibody results, while Norway reported similar numbers around 10%. Rates drop lower in places like the Middle East (4-9%), Korea, and China, pointing to the roles of genes, diet, and local environments in shaping these patterns [8].



Fig 03: LADA Statistics

Statistically, LADA affects 2-12% of all adult diabetes cases worldwide, with most prevalence in Caucasian populations of Europe and North America in comparsion to Asian or Middle Eastern groups. A Swedish cohort study pegged it at 10% of adult-onset diabetes, during Japan's Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial noted just 4-5%- associated to stronger genetic protections against autoimmunity in East Asians. In India, rising data from urban clinics suggest 5-8% of type 2 diagnoses may involve LADA, influenced by rising obesity and hybrid genetic factors in diverse populations. Women tend to overpower men in LADA cases by 1.5-2:1, often striking between ages 35-60, though it can emerge later. Longitudinal UK Prospective Diabetes Study (UKPDS) follow-ups showed 10-20% advancement to insulin necessity within 5-6 years, reinforce its slow-burn nature versus classic type 1 [9].

Approximately all LADA cases involve one or more islet autoantibodies, with GAD antibodies leading the pack in 70-90% of patients- though profiles differs by region, like higher IA-2 occurance in some Asian cohorts. A single antibody test remains short since levels fluctuate over time, sometimes disguised by counteracting anti-idiotype factors. Addition to it, LADA doesn't stick to adults only; cases could also showed up in adolescents and young adults too, blurring lines with early-onset type 1 [10].

PATHOPHYSIOLOGY OF LADA

LADA, or Latent Autoimmune Diabetes in Adults, develops through a slow autoimmune process that targets and attacks the beta cells in the pancreas responsible for insulin production. This damage typically initiates years before any symptoms show up, steadily impairing the cells' insulin output until blood sugar levels rise into hyperglycemia. What makes LADA unique is how it combines the autoimmune destruction seen in type 1 diabetes- where the body's immune system mistakenly targets its own beta cells- with elements of insulin resistance typically associated with type 2 diabetes, such as reduced effectiveness of insulin in tissues like muscle and fat [11].



Fig 04: Type 1.5 Diabetes Mechanism

Even when researchers adjust for differences in body mass index (BMI), people with LADA frequently show levels of insulin resistance that rival those in type 2 diabetes patients. This resistance means their bodies don't respond as well to insulin, forcing the pancreas to work harder until the beta cell damage catches up. A subset of LADA patients also develops features of metabolic syndrome, including high blood pressure, abnormal cholesterol profiles, and over abdominal fat, though these are less common than in classic type 2 diabetes. Factors like genetics (e.g., certain HLA gene variants), environmental triggers (such as viral infections), and lifestyle changes (including obesity or sedentary habits) can accelerate this hybrid progression [12].

Spotting LADA can be tricky since it frequently looks like type 2 diabetes at first, particularly in slimmer adults over 30 who don't depend on insulin immediately. Telltale signs are autoantibodies such as GAD65 or islet cell antibodies, along with low C-peptide (showing reduced insulin output), and a progression that's slower than type 1. Treatment often kicks off with pills like metformin for insulin resistance, though most people end up needing insulin as beta cells fail—usually 5-10 years after diagnosis. Catching it early via antibody tests helps tailor care and may postpone issues like nerve damage, eye problems, or heart disease, which overlap with risks from type 1 and type 2 [13].

IMMUNOLOGICAL MECHANISM

The immune system functions in LADA alters from those in type 1 diabetes. Pancreatic islets in LADA confirms infiltration primarily by macrophages, other than T-cells. This is connected to increased levels of pro-inflammatory cytokines as interleukin-1β, along with anti-inflammatory ones such as interleukin-10and lower expression of apoptosis markers. Accordingly, beta-cell destruction and disease development occur more slowly than in type 1 diabetes.

Any individual with LADA who diagnosed positive for multiple diabetes-related autoantibodies experience increased beta-cell loss and faster insulin dependency. The dependability of particular autoantibodies, like glutamic acid decarboxylase antibodies (GADA), can alter by age and population group [14].

Autoantibodies and Immune Differences

Glutamic acid decarboxylase antibodies, or GADA, represent the most repeatedly detected autoantibody in adults with latent autoimmune diabetes (LADA). It explains, their usefulness in detecting LADA differs by location and ethnic background, so they're not reliable on their own. Individuals with LADA often experience a higher incidence of accompanying autoimmune conditions- gut or thyroid disorders- than people with straightforward type 2 diabetes. In these patients, regulatory T cells, which usually keep autoimmune reactions in check, won't perform perfectly. It happens due todecreased amounts of key proteins like FOXP3, leading to low immune self-tolerance. As an unintended, the pancreas's beta cells take more of a hit, mainly when antibody levels run high [15].

Genetic Influences

Genetically, LADA aligns more closely with type 1 diabetes than type 2. People at higher risk for LADA typically carry specific variants in immune-related genes, such as those in the HLA complex. That said, the overall genetic risk for LADA is milder than for type 1 diabetes, which may explain its later onset. Meanwhile, genetic factors linked to type 2 diabetes show only weak connections to LADA.

Metabolic and Inflammatory Features

Latent Autoimmune Diabetes in Adults (LADA) is a varied condition, with some patients showing signs of insulin resistance and excess body weight. These individuals often have raised levels of inflammation markers typically seen in metabolic conditions. Research also highlights a link between higher body weight and increased pro-inflammatory cytokines.

Other Key Points

Unlike Type 1 diabetes, LADA lacks specific environmental triggers. That said, therapies that adjust immune responses-particularly those targeting T-cells-hold promise for future treatments.

Background and Symptoms

People with LADA typically experience classic hyperglycemia symptoms like frequent urination, excessive thirst, nocturia, tiredness, blurry vision, numbness in the limbs, and unintended weight loss. Some cases remain symptom-free, which is a notable feature of LADA.

Risk Factors and Diagnostic Hints

Certain clues in a patient's history can suggest LADA:

- Personal or family history of autoimmune conditions, similar to Type 1 diabetes.
- Low birth weight, a factor shared with Type 2 diabetes.
- Lifestyle habits such as smoking, alcohol use, and high intake of sugary drinks.
- Low levels of physical activity, which contribute to metabolic risks.

It's also essential to accurately assess blood pressure and other metabolic indicators.

Screening and Diagnostic Tools for LADA

Various clinical assessments help detect individuals at risk for latent autoimmune diabetes in adults (LADA).

SCREENING CRITERIA (FOR PATIENTS OVER 50 YEARS)

One recommended approach involves these indicators:

1. Low or normal body mass index (BMI).
2. Inadequate blood sugar management despite lifestyle changes (e.g., fasting plasma glucose exceeding 270 mg/dL or HbA1c above 10%).
3. Unexplained weight loss even with sufficient calorie consumption.

This method effectively flags a notable portion of LADA cases.

CLINICAL RISK SCORE

A widely applied scoring tool considers these factors:

1. Age under 50 years.
2. Symptoms of high blood sugar.
3. BMI below 25 kg/m². '
4. Personal history of autoimmune conditions.
5. Family history of autoimmune disorders.

Having two or more of these suggests LADA is likely; fewer than two indicates lower probability.

Clinical Characteristics [16]

LADA symptoms can mimic type 1 diabetes, type 2 diabetes, or fall somewhere in between, such as:

- Intermediate BMI, waist size, blood pressure, and lipid levels compared to type 1 and type 2 patients.
- Partial features of metabolic syndrome.

Experts describe two LADA subtypes based on autoantibody levels:

- **LADA1**: Elevated glutamic acid decarboxylase (GAD) antibodies, low BMI, reduced C-peptide, and type 1-like features.
- **LADA2**: Minimal or single autoantibody presence, with type 2-like traits.

At diagnosis, most LADA patients lack ketosis, aligning their presentation more closely with type 2 diabetes.

Recognizing and Diagnosing LADA

Latent Autoimmune Diabetes in Adults (LADA) warrants consideration in adults presenting with high blood sugar-whether symptomatic or not-who can control their glucose without insulin during the initial six months after diagnosis [17].

The defining feature of LADA is the presence of autoantibodies targeting pancreatic islet cells. Globally, the primary autoantibody tested is glutamic acid decarboxylase antibody (GADA).

Assessing C-Peptide Levels

People with LADA retain some beta-cell function, reflected in C-peptide levels that fall between those seen in type 1 and type 2 diabetes. These levels typically decrease as GADA concentrations rise. Tests using stimulated C-peptide provide stronger prognostic insights than fasting ones [18]. Two reliable stimulation approaches include:

Glucagon Stimulation Test: Quicker to perform, though it can briefly trigger nausea.

Mixed Meal Tolerance Test (MMTT): Takes more time but is generally comfortable with no adverse effects.

Opting for C-peptide over insulin measurement makes sense due to its extended half-life, consistent elimination, and lack of liver metabolism interference. Exogenous insulin also skews direct insulin readings.

Beyond diagnosis, C-peptide results guide therapy choices and forecast when insulin might become necessary. Studies show LADA patients have lower C-peptide than those with type 2 diabetes. While cost-efficient, C-peptide alone doesn't confirm LADA—autoantibody testing is essential. HLA typing isn't standard in routine care [19].

Standard and Suggested Tests [20]

LADA management mirrors general diabetes protocols, tailored to the individual's health:

- Fasting blood glucose
- HbA1c
- Self-monitored blood glucose
- Glucose fluctuation tracking, ideally via continuous glucose monitoring
- Lipid panel
- Renal function: creatinine and eGFR
- Urine albumin: spot sample or 24-hour collection
- Peripheral nerve evaluation: Semmes-Weinstein monofilament
- Eye exam for retinopathy: performed by an ophthalmologist

Additional tests may address emerging diabetes complications as needed.

Non-Drug Approaches

After diagnosing LADA (latent autoimmune diabetes in adults), start with lifestyle adjustments similar to those for type 1 or type 2 diabetes. These include:

- Personalized nutrition plans tailored to the individual's needs.
- Regular physical activity programs.
- Strategies for maintaining a healthy weight.

While these steps offer short-term benefits, they often prove insufficient over time as the disease advances.

DRUG-BASED TREATMENT [21]

Pharmacological options for LADA are customized per patient, focusing on two goals: achieving tight blood sugar control and preserving beta-cell function to postpone diabetes complications.

Insulin as the Cornerstone

Insulin remains the primary therapy for LADA.

- Start insulin right away if C-peptide levels are low at diagnosis.
- Initiating insulin early helps sustain beta-cell activity, boosts C-peptide production, reduces autoantibody levels, and keeps HbA1c in a healthy range.
- Patients must check blood glucose frequently and tweak doses, since needs can fluctuate daily.
- As LADA worsens and natural insulin output drops, reliance on insulin grows.

Oral Medications [22]

Because LADA progresses gradually, some patients initially benefit from type 2 diabetes drugs, though results vary.

Sulfonylureas

- Typically discouraged, as they can speed up beta-cell exhaustion, leading to faster drops in C-peptide and earlier insulin dependence.

Metformin

- Enhances insulin sensitivity, supports weight reduction, and may help avert complications.
- Limited data exists for LADA specifically, with mixed expert views on its value.

Thiazolidinediones (TZDs)

- Boost insulin sensitivity by targeting PPAR-γ receptors.
- Study outcomes differ: rosiglitazone may protect beta-cells, but pioglitazone has hastened C-peptide decline in certain cases.
- Risks include weight gain, fluid buildup, heart failure, bone fractures, and macular edema. Long-term effectiveness in LADA needs further investigation.

INCRETIN THERAPIES

DPP-4 Inhibitors [23]

- Elevate natural GLP-1, curb glucagon, and promote meal-related insulin release.
- They might also temper autoimmune attacks on beta-cells via effects on T-cells.
- These agents improve blood sugar management and could help protect beta-cells in LADA.

GLP-1 Receptor Agonists

- Evidence is sparse for LADA.
- Drugs like dulaglutide have lowered HbA1c in broader diabetes groups, but dedicated LADA trials are needed to confirm benefits.

MANAGEMENT APPROACH FOR LADA

Treating Latent Autoimmune Diabetes in Adults (LADA) aims to ease high blood sugar symptoms, ward off chronic complications, and support a typical daily life. Key elements of care involve:

- Dietary changes and structured nutrition plans
- Checking and addressing high blood pressure and elevated cholesterol
- Regular checks and care for kidney issues and eye damage
- Ongoing assessments of metabolic and heart health

DIAGNOSTIC AND TRACKING METHODS [24]

Autoantibodies are essential for confirming LADA, though not every doctor tests for them in every case.

C-peptide measurements help gauge beta cell activity, guiding treatment choices and predicting how quickly insulin needs may develop.

Tailoring Care to Patient Traits

People who are overweight often get diagnosed with type 2 diabetes without LADA testing.

Those at a healthy weight with elevated glucose are more likely to undergo LADA screening.

TREATMENT OBJECTIVES

The focus is on tight blood sugar control while protecting beta cells and natural insulin output, which links to better overall health and outlook.

Research indicates beta cell recovery is possible even after diabetes symptoms appear, via immune-regulating processes involving cytokines.

AUTOIMMUNE FACTORS

LADA shares genetic risks with conditions like thyroid autoimmunity, gluten intolerance, and adrenal insufficiency.

Testing for organ-specific autoantibodies can spot people prone to additional autoimmune issues.

ONGOING CHALLENGES

Despite LADA's frequency, dedicated treatment protocols are lacking.

Care must be personalized to maximize benefits and slow beta cell decline.

DIFFERENTIATING LADA FROM OTHER DIABETES TYPES [25]

Distinguishing Latent Autoimmune Diabetes in Adults (LADA) from Type 2 diabetes poses a significant challenge in managing adult-onset diabetes, as their symptoms often overlap. Unlike Type 2 diabetes patients-who typically test negative for islet cell autoantibodies and show high fasting or stimulated C-peptide levels-LADA cases eventually require insulin sooner.

Clinicians should consider LADA in Type 2 diabetes patients whose blood sugar remains poorly controlled despite best efforts. Heightened suspicion is warranted for lean individuals without metabolic syndrome or personal/family history of autoimmune conditions like Hashimoto's thyroiditis, Graves' disease, celiac disease, rheumatoid arthritis, or pernicious anemia.

Type 1 diabetes stands apart from LADA due to its acute features, such as extreme hyperglycemia or ketoacidosis, demanding prompt insulin. Maturity-Onset Diabetes of the Young (MODY) mimics LADA clinically but features strong family history, sustained C-peptide, and no islet autoantibodies [26].

LADA typically emerges after age 30–40 and gets misdiagnosed as Type 2. Patients respond initially to oral agents like metformin, but declining beta-cell function leads to insulin needs faster than in true Type 2 cases. A weak or short-lived response to these drugs signals possible LADA.

DIAGNOSTIC APPROACH

Standard diabetes tests include:

- Fasting plasma glucose after ≥8 hours without food.
- 2-hour oral glucose tolerance test post-glucose load.
- Random plasma glucose, regardless of last meal.

LADA Diagnostic Criteria

The Immunology of Diabetes Society outlines these for LADA:

1. Adult onset (generally >30 years).
2. No insulin required within 6 months of diagnosis.
3. At least one Type 1 diabetes-associated autoantibody.

These criteria have caveats: adult onset can occur earlier, and some patients need insulin sooner.

KEY ROLE OF AUTOANTIBODIES

Autoantibodies are central to confirming LADA. Glutamic acid decarboxylase antibodies (GADA) offer the highest sensitivity and are the go-to test. Islet cell antibodies (ICA), insulin autoantibodies (IAA), and IA-2 antibodies appear less often in LADA. Elevated GADA levels predict faster beta-cell loss and earlier insulin dependence, helping subclassify LADA by progression speed [27].

The Diabetes Antibody Standardization Program (DASP 2009) confirmed strong performance: GADA excels in sensitivity, IA-2 in specificity. Still, screening all adult diabetes cases isn't standard, as it hasn't proven to improve long-term results.

CLINICAL IMPLICATIONS

People with autoantibodies tend to become insulin-dependent more quickly, but those without them can still progress to this stage over time. The key to effective management lies in routine blood glucose monitoring and starting insulin when clinically indicated.

Table 02: Assays for islet auto-antibodies

ANTIBODY	ASSAY METHODS	REMARKS
Glutamic acid decarboxylase antibody	Radioimmunoassay (RIA), enzyme-linked immunosorbent assay	Generally RIA methods are used for these antibodies, but inconvenience of dealing with radioisotope has made ELISA developed for clinical utilization.
Insulin auto-antibodies Islet antigen 2 Islet cell antibodies	Enzyme-linked immunosorbent assay	Because ICA assays are difficult to standardize, their use has declined substantially.

In certain cases, autoantibody testing remains useful. For instance

- Adults with just a single autoantibody face no elevated risk of needing insulin soon.
- Younger patients with multiple autoantibodies are much more likely to require insulin earlier.

Considerations for Counselling

These insights are vital for educating patients and tailoring treatment plans to their needs.

C-Peptide

C-peptide levels offer a dependable measure of the body's own insulin production and β-cell performance in the pancreas. Released alongside insulin in equal amounts, C-peptide bypasses significant liver breakdown and exits the blood at a steady pace. Low C-peptide signals reduced β-cell function and insulin output, signaling the need to begin insulin treatment.

PROGNOSIS OF LADA

Individuals with Latent Autoimmune Diabetes in Adults (LADA) face a mortality risk comparable to those with type 2 diabetes. Even with a generally better metabolic makeup, they remain vulnerable. Data from the Trøndelag Health (HUNT) study highlight that cardiovascular mortality in LADA stems mainly from high blood sugar, not metabolic syndrome [28].

Tight blood glucose control is essential to enhance long-term results and cut complication risks in LADA.

Patients with latent autoimmune diabetes in adults (LADA) typically show fewer microvascular complications at diagnosis compared to those with type 2 diabetes mellitus (T2DM). Over time, however, LADA patients experience higher rates of these issues, including elevated cardiovascular risks relative to T2DM.

Neuropathy

- Small fiber neuropathy occurs more frequently and starts earlier in LADA than in T2DM.
- Its severity correlates with higher HbA1c levels and inadequate blood glucose management.
- Large fiber neuropathy rates are comparable between LADA and T2DM.
- Screening for small fiber neuropathy should be part of routine LADA assessment.

Long-Term Complications

- In the initial 9 years after diagnosis, LADA patients have fewer microvascular complications than those with T2DM.
- Beyond that period, LADA is associated with greater complication rates than T2DM.
- Carotid artery atherosclerosis in LADA resembles levels seen in both type 1 and type 2 diabetes, though overall vascular risk profiles tend to be less severe.

CARDIOVASCULAR DISEASE

Studies like Botnia, Freemantle Diabetes, and HUNT have shown that latent autoimmune diabetes in adults (LADA) carries a higher risk of cardiovascular disease and mortality compared to type 2 diabetes mellitus.

Overall, LADA links to both microvascular and macrovascular issues more severely than type 1 or type 2 diabetes.

PATIENT EDUCATION AND PREVENTIVE MEASURES IN LADA

It's crucial to educate adults with LADA about their condition and the need for tight glycemic control to prevent microvascular and macrovascular problems. Key strategies include:

- Tailored medical nutrition therapy
- Medications like oral hypoglycemics or insulin
- Regular self-monitoring of blood glucose
- Awareness of microvascular risks (e.g., neuropathy, retinopathy, nephropathy)
- Awareness of macrovascular risks (e.g., cardiovascular disease)

For those on SGLT2 inhibitors, stress the risk of ketoacidosis-advise ketone monitoring, even if blood glucose isn't very high.

KEY FEATURES OF LADA [29]

- Latent Autoimmune Diabetes in Adults (LADA) combines traits of both type 1 and type 2 diabetes.
- Timely diagnosis is essential to enable effective treatment and reduce long-term risks.
- Screen for LADA in adults diagnosed with type 2 diabetes who fail to achieve good blood sugar control despite medication compliance—especially if they are lean, lack metabolic syndrome signs, or have autoimmune conditions in their family history.
- Research shows β-cell loss in the pancreas progresses slowly in LADA, accounting for its gradual onset.
- Measuring C-peptide levels (fasting or after a mixed-meal test) offers a cost-effective initial check to identify candidates for advanced testing.
- Avoid sulfonylureas, as they may accelerate β-cell depletion and hasten insulin dependence.
- Preferred treatments like insulin, DPP-4 inhibitors, thiazolidinediones, and GLP-1 agonists help maintain blood sugar stability while protecting β-cell function.
- When using SGLT2 inhibitors, advise patients about diabetic ketoacidosis risks and the importance of regular ketone monitoring.

IMPROVING HEALTHCARE TEAM RESULTS IN LADA

World Health Organization reports that diabetes impacts hundreds of million people globally. LADA results4%–12% of cases misidentified as type 2, suggesting it affects a significant population [30].

Primary care providers often observe LADA first and must recognize it early stages to guide effective care.

Endocrinologists lead complex cases, collaborating with specialists like ophthalmologists, podiatrists, and geneticists.

Bariatric surgeons should consider LADA in diabetic patients who don't improve glycemic control post-surgery.

A collaborative, team-based strategy across disciplines ensures better blood sugar management, slows complications, and cuts down on illness, death, and treatment expenses tied to LADA.

LADA'S PLACE IN THE DIABETES SPECTRUM

Diabetes mellitus exists on a sequency, with Type 1 and Type 2 at opposite ends. Type 1 stems from autoimmune damage to the pancreas, Latent Autoimmune Diabetes in Adults (LADA) exhibits a combination of features from both diabetes types, leading to ongoing discussions regarding its root causes. This form of diabetes often presents diagnostic challenges because it shares symptoms with both Type 1 and Type 2 diabetes. Researchers continue to study LADA to better understand its development and to improve treatment strategies tailored to its unique characteristics [31].

The influence of obesity and insulin resistance in LADA residue unclear. Research shows that insulin resistance in LADA patients is milder than in Type 2 diabetes and often similar to levels in Type 1. When excluding glucose-related factors, metabolic syndrome rates in autoimmune diabetes match those in people without diabetes.

Table 03: Comparison of markers in type 1 diabetes mellitus, latent autoimmune diabetes of adults, and type 2 diabetes mellitus

Genetic/ Other Markers	Type-1 Diabetes Mellitus	LADA	Type-2 Diabetes Mellitus
Islet cell antibodies	Positive, may test positive before onset	Positive, helps differentiation from Type-2 Diabetes Mellitus	Negative
Insulin auto-antibody	Often detected	Often Detected	Negative
Islet Antigen 2	Often positive in newly diagnosed Type-1 Diabetes mellitus	Often Detected	Negative
Glutamic acid decarboxylase antibody	Common in adults than in children	More common than in Type-1 Diabetes Mellitus	Rare, Positive may indicate LADA
HLA- link Insulin/ C Peptides	High Very low	Low Low	Negative Normal to high

Genetically, Type 1 diabetes links strongly to HLA genes, a connection absent in Type 2. LADA shows a milder HLA association than Type 1, potentially explaining its later onset in adulthood.

Pathologically, Type 1 characteristics intense islet cell inflammation, which appears in LADA but it decreases the intensity. This milder inflammation may initially shield beta cells from rapid destruction, leading to gradual progression of disease. Factors like islet autoantibodies and inflammation markers can signal faster insulin needs.

Unlike Type 2 diabetes, which involves widespread inflammation indicated by elevated levels of markers like C-reactive protein, tumour necrosis factor, and interleukins, LADA does not display this substantial substantial inflammatory response. Instead, its immune activity is primarily focused on the pancreatic islets [32].

Regarding beta-cell function, individuals with LADA initially have higher C-peptide levels compared to those with typical Type 1 diabetes, which postpones the need for insulin therapy. However, as beta-cell function declines over time, they eventually require insulin similar to Type 1 patients. In contrast, people with Type 2 diabetes usually maintain normal or elevated C-peptide levels.

LADA acts as a bridge between Type 1 and Type 2, with age at diagnosis playing a vital role-later onset preserves more beta-cell function than in typical Type 1.

MANAGING SUSPECTED LADA CASES

Diabetes management differs by type:

Type 1 patients need insulin right away, while Type 2 starts without it but may progress to dependence. Not every case fits neatly into Type 1 or 2. Adults emulating the Type 2 but harboring autoimmune traits fall into LADA.

LADA occurs in adults who initially do not require insulin and show clinical features similar to Type 2 diabetes, but they test positive for autoimmune markers associated with Type 1, such as islet cell or GAD antibodies. Over time, these individuals generally become insulin-dependent within a few years [33].

The UK Prospective Diabetes Study (UKPDS) found that some Type 2 diagnoses hid antibody positivity. Those with both islet cell and GAD antibodies faced more rapid insulin requisite than antibody-negative peers.

CLINICAL INDICATORS FOR SUSPECTING LADA [34]

Individuals with LADA typically begin blood sugar management using oral medications. A rapid decline in the impact of these drugs may indicate autoimmune diabetes. Some characteristics are most commonly found in LADA compared to type 2 diabetes, assisting in the identification of possible cases.

LADA CLINICAL RISK SCORE

Researchers have identified five key traits to distinguish LADA from type 2 diabetes:

1. Diabetes starting before age 50 years.
2. Classic symptoms like intense thirst, frequent urination, or unexplained weight loss.
3. BMI below 25 kg/m².
4. Personal history of autoimmune conditions.
5. Family history of autoimmune disorders.

Scoring two or more of these (a risk score of ≥2) offers about 90% sensitivity and 71% specificity for LADA. A score of 1 or lower suggests LADA is unlikely.

LIMITS OF CLINICAL EVALUATION

This scoring method isn't definitive for diagnosing LADA on its own. Factors like age, BMI, and autoimmune history differ widely across populations, and symptoms of high blood sugar occur in all diabetes types. It serves mainly as a screening tool to identify candidates for autoantibody tests, enabling earlier and more precise LADA identification.

IMMUNE THERAPIES FOR LADA [35]

LADA stems from the immune system targeting pancreatic β-cells. As an autoimmune condition, it might respond to treatments that promote tolerance toward these cells and slow disease progression.

Emerging immune therapies show potential in autoimmune diabetes:

- Peptide-based drugs from heat shock protein 60, like DiaPep277, which helps to sustain the β-cell function in adults.
- GAD65 vaccines (e.g., Diamyd), which boost C-peptide levels and maintain natural insulin output.
- Anti-CD3 monoclonal antibodies, which protect β-cells, enhance insulin production, lower HbA1c, and cut insulin needs.
- While promising for LADA, these options require more studies to prove their effectiveness.

Potential of Incretin Therapies

GLP-1 receptor agonists and DPP-4 inhibitors-common for type 2 diabetes-might asset LADA patients too. Examples include:

- GLP-1 agonists like exenatide and liraglutidev.
- DPP-4 inhibitors like sitagliptin.

These can boost insulin release in response to meals. Still, their long-term value in LADA remains unclear, pending additional research.

CONCLUSION

Latent Autoimmune Diabetes in Adults (LADA) makes up a notable fraction of all diabetes cases. When lumped together with Type 1 diabetes, it boosts the total number of people who will eventually rely on insulin. Unlike the rapid onset of Type 1, LADA develops slowly, which opens doors for early action. Treating LADA focuses on preserving pancreatic β-cell activity and pushing back insulin reliance. Total prevention of progression isn't realistic, but catching

high-risk patients supports perceptive management and stronger results. Using the LADA clinical risk score, providers divide cases into low-risk (≤1 point) and high-risk (≥2 points). Tests for autoantibodies like GADA deliver excellent diagnostic precision. Sulfonylurea are not recommended for LADA, since they risk speeding up β-cell burnout. Metformin suits patients who are overweight and show insulin resistance, with vigilance needed for insulin supply issues. Drugs like thiazolidinediones or incretins might aid β-cell protection but effects are only moderate.

Insulin is the go-to therapy for LADA, introduced when C-peptide drops or symptoms demand it—ideally at an early stage. That said, patient reluctance to start insulin soon often complicates care in real-world practice.

FUNDING
Nil

INFORM CONSENT AND ETHICAL CONSIDERATIONS
Not Applicable

ACKNOWLEDGEMENT
Not Declared

AUTHOR CONTRIBUTIONS
All authors are contributed equally

CONFLICT OF INTEREST
Not Declared.

REFERENCES

1. Mayo Clinic Staff, "Diabetes," Mayo Clinic, last modified July 11, 2023, https://www.mayoclinic.org/diseases-conditions/diabetes/symptoms-causes/syc-20371444
2. Mayo Clinic Staff. **"Diabetic Ketoacidosis: Symptoms and Causes".** Mayo Clinic. Last modified March 16, 2023. https://www.mayoclinic.org/diseases-conditions/diabetic-ketoacidosis/symptoms-causes/syc-20371551
3. Pieralice S, Pozzilli P. Latent Autoimmune Diabetes in Adults: A Review on Clinical Implications and Management. Diabetes Metab J. 2018 Dec;42(6):451-464. doi: 10.4093/dmj.2018.0190. PMID: 30565440; PMCID: PMC6300440.
4. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464:1293–1300. doi: 10.1038/nature08933. [DOI] [PMC free article] [PubMed] [Google Scholar]
5. 2.Mishra R, Hodge KM, Cousminer DL, Leslie RD, Grant SFA. A global perspective of latent autoimmune diabetes in adults. Trends Endocrinol Metab. 2018;29:638–650. doi: 10.1016/j.tem.2018.07.001. [DOI] [PubMed] [Google Scholar]
6. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care. 2001;24:1460–1467. doi: 10.2337/diacare.24.8.1460. [DOI] [PubMed] [Google Scholar]
7. 7.American Diabetes Association. (2) Classification and diagnosis of diabetes. Diabetes Care. 2015;38(Suppl):S8–S16. doi: 10.2337/dc15-S005. [DOI] [PubMed] [Google Scholar]
8. 8.Leslie RD, Williams R, Pozzilli P. Clinical review: type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab. 2006;91:1654–1659. doi: 10.1210/jc.2005-1623.
9. Sabbah E, Savola K, Ebeling T, Kulmala P, Vahasalo P, Ilonen J, Salmela PI, Knip M. Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care. 2000;23:1326–1332. doi: 10.2337/diacare.23.9.1326. [DOI] [PubMed] [Google Scholar]
10. 12.Howson JM, Rosinger S, Smyth DJ, Boehm BO ADBW-END Study Group. Todd JA. Genetic analysis of adult-onset autoimmune diabetes. Diabetes. 2011;60:2645–2653. doi: 10.2337/db11-0364
11. Park Y, Wintergerst KA, Zhou Z. Clinical heterogeneity of type 1 diabetes (T1D) found in Asia. Diabetes Metab Res Rev. 2017;33:e2907. doi: 10.1002/dmrr.2907.
12. Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017;13:674–686. doi: 10.1038/nrendo.2017.99
13. Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab. 2009;94:4635–4644. doi: 10.1210/jc.2009-1120.
14. Rawshani A, Landin-Olsson M, Svensson AM, Nystrom L, Arnqvist HJ, Bolinder J, Gudbjornsdottir S. The incidence of diabetes among 0–34 year olds in Sweden: new data and better methods. Diabetologia. 2014;57:1375–1381. doi: 10.1007/s00125-014-3225-9
15. Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI ADOPT Study Group. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes. 2004;53:3193–3200. doi: 10.2337/diabetes.53.12.3193.
16. Qi X, Sun J, Wang J, Wang PP, Xu Z, Murphy M, Jia J, Wang J, Xie Y, Xu W. Prevalence and correlates of latent autoimmune diabetes in adults in Tianjin, China: a population-based cross-sectional study. Diabetes Care. 2011;34:66–70. doi: 10.2337/dc10-0488

17. Lee SH, Kwon HS, Yoo SJ, Ahn YB, Yoon KH, Cha BY, Lee KW, Son HY. Identifying latent autoimmune diabetes in adults in Korea: the role of C-peptide and metabolic syndrome. Diabetes Res Clin Pract. 2009;83:e62–e65. doi: 10.1016/j.diabres.2008.11.031.
18. Britten AC, Jones K, Torn C, Hillman M, Ekholm B, Kumar S, Barnett AH, Kelly MA. Latent autoimmune diabetes in adults in a South Asian population of the U.K. Diabetes Care. 2007;30:3088–3090. doi: 10.2337/dc07-0896.
19. Sachan A, Zaidi G, Sahu RP, Agrawal S, Colman PG, Bhatia E. Low prevalence of latent autoimmune diabetes in adults in northern India. Diabet Med. 2015;32:810–813. doi: 10.1111/dme.12644
20. Field SF, Howson JM, Smyth DJ, Walker NM, Dunger DB, Todd JA. Analysis of the type 2 diabetes gene, TCF7L2, in 13,795 type 1 diabetes cases and control subjects. Diabetologia. 2007;50:212–213. doi: 10.1007/s00125-006-0506-y
21. Qu HQ, Grant SF, Bradfield JP, Kim C, Frackelton E, Hakonarson H, Polychronakos C. Association analysis of type 2 diabetes Loci in type 1 diabetes. Diabetes. 2008;57:1983–1986. doi: 10.2337/db08-0270
22. Desai M, Zeggini E, Horton VA, Owen KR, Hattersley AT, Levy JC, Walker M, Gillespie KM, Bingley PJ, Hitman GA, Holman RR, McCarthy MI, Clark A. An association analysis of the HLA gene region in latent autoimmune diabetes in adults. Diabetologia. 2007;50:68–73. doi: 10.1007/s00125-006-0513-z.
23. Andersen MK, Lundgren V, Turunen JA, Forsblom C, Isomaa B, Groop PH, Groop L, Tuomi T. Latent autoimmune diabetes in adults differs genetically from classical type 1 diabetes diagnosed after the age of 35 years. Diabetes Care. 2010;33:2062–2064. doi: 10.2337/dc09-2188.
24. Barinas-Mitchell E, Pietropaolo S, Zhang YJ, Henderson T, Trucco M, Kuller LH, Pietropaolo M. Islet cell autoimmunity in a triethnic adult population of the Third National Health and Nutrition Examination Survey. Diabetes. 2004;53:1293–1302. doi: 10.2337/diabetes.53.5.1293.
25. Buzzetti R, Spoletini M, Zampetti S, Campagna G, Marandola L, Panimolle F, Dotta F, Tiberti C NIRAD Study Group (NIRAD 8) Tyrosine phosphatase-related islet antigen 2(256-760) autoantibodies, the only marker of islet autoimmunity that increases by increasing the degree of BMI in obese subjects with type 2 diabetes. Diabetes Care. 2015;38:513–520. doi: 10.2337/dc14-1638.
26. Hjort R, Ahlqvist E, Carlsson PO, Grill V, Groop L, Martinell M, Rasouli B, Rosengren A, Tuomi T, Asvold BO, Carlsson S. Overweight, obesity and the risk of LADA: results from a Swedish case-control study and the Norwegian HUNT Study. Diabetologia. 2018;61:1333–1343. doi: 10.1007/s00125-018-4596-0.
27. 48.Leslie RD, Kolb H, Schloot NC, Buzzetti R, Mauricio D, De Leiva A, Yderstraede K, Sarti C, Thivolet C, Hadden D, Hunter S, Schernthaner G, Scherbaum W, Williams R, Pozzilli P. Diabetes classification: grey zones, sound and smoke: Action LADA 1. Diabetes Metab Res Rev. 2008;24:511–519. doi: 10.1002/dmrr.877.
28. Genovese S, Bazzigaluppi E, Goncalves D, Ciucci A, Cavallo MG, Purrello F, Anello M, Rotella CM, Bardini G, Vaccaro O, Riccardi G, Travaglini P, Morenghi E, Bosi E, Pozzilli P. Clinical phenotype and beta-cell autoimmunity in Italian patients with adult-onset diabetes. Eur J Endocrinol. 2006;154:441–447. doi: 10.1530/eje.1.02115.
29. Desai M, Cull CA, Horton VA, Christie MR, Bonifacio E, Lampasona V, Bingley PJ, Levy JC, Mackay IR, Zimmet P, Holman RR, Clark A. GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77. Diabetologia. 2007;50:2052–2060. doi: 10.1007/s00125-007-0745-6.
30. Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, Colman PG. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care. 2006;29:970–975. doi: 10.2337/diacare.295970.
31. Monge L, Bruno G, Pinach S, Grassi G, Maghenzani G, Dani F, Pagano G. A clinically orientated approach increases the efficiency of screening for latent autoimmune diabetes in adults (LADA) in a large clinic-based cohort of patients with diabetes onset over 50 years. Diabet Med. 2004;21:456–459. doi: 10.1111/j.1464-5491.2004.01177.x.
32. Davis AK, DuBose SN, Haller MJ, Miller KM, DiMeglio LA, Bethin KE, Goland RS, Greenberg EM, Liljenquist DR, Ahmann AJ, Marcovina SM, Peters AL, Beck RW, Greenbaum CJ T1D Exchange Clinic Network. Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care. 2015;38:476–481. doi: 10.2337/dc14-1952.
33. Pipi E, Marketou M, Tsirogianni A. Distinct clinical and laboratory characteristics of latent autoimmune diabetes in adults in relation to type 1 and type 2 diabetes mellitus. World J Diabetes. 2014;5:505–510. doi: 10.4239/wjd.v5.i4.505
34. George P, McCrimmon RJ. Potential role of non-insulin adjunct therapy in type 1 diabetes. Diabet Med. 2013;30:179–188. doi: 10.1111/j.1464-5491.2012.03744.x.
35. Zhou Z, Li X, Huang G, Peng J, Yang L, Yan X, Wang J. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA) Diabetes Metab Res Rev. 2005;21:203–208. doi: 10.1002/dmrr.503.